重症超声指导间歇性血液滤过容量管理治疗急性肾损伤
该研究纳入2019年4月至2022年6月天津市第三中心医院冠心病监护病房(CCU)收治的216例心力衰竭合并急性肾损伤并接受间歇性静脉-静脉血液滤过(IVVH)治疗的患者,随机分为常规指导组(107例)和超声指导组(109例)。超声指导组在常规方法基础上使用重症超声调整IVVH治疗参数,记录下腔静脉呼吸变异指数、左右心室舒张末期横截面积比、E/E'、主动脉血流速度时间积分、心输出量、双肺B线范围及双侧肾叶间动脉阻力指数,并据此实时调整净脱水率。结果显示超声指导组早期β2-微球蛋白和胱抑素C下降更快,7天时尿量、血肌酐和估算肾小球滤过率改善更显著,且血肌酐恢复时间、多尿期到达时间、IVVH总治疗时间、无创机械通气时间和CCU住院时间均短于常规指导组,低血压、长期肾脏替代治疗、主要心血管不良事件和28天死亡率均更低。
要点
- 超声指导组在IVVH开始时脱水率较慢,6小时后逐渐增加,总体脱水率显著慢于常规指导组。
- 超声指导组使用重症超声后下腔静脉呼吸变异指数逐渐升高,左右心室舒张末期面积比逐渐降低,E/E'比值逐渐降低,双肺B线范围逐渐缩小,双侧肾叶间动脉阻力指数降低。
- 首次IVVH后3天,超声指导组β2-微球蛋白(mg/L)3.69±1.31 vs 常规指导组3.99±1.45,胱抑素C(mg/L)2.91±0.95 vs 3.14±0.96,均P<0.05。
- 7天时超声指导组24小时尿量(mL)1 128.23±153.92 vs 1 015.01±114.18,血肌酐(μmol/L)145.86±32.25 vs 155.64±28.42,估算肾小球滤过率(mL/min)50.26±11.24 vs 46.51±10.61,均P<0.05。
- 超声指导组低血压、长期肾脏替代治疗、主要心血管不良事件和28天死亡率均低于常规指导组;Kaplan-Meier曲线显示超声指导组28天累积生存率显著低于常规指导组(Log-Rank检验:χ2=3.903,P=0.048),原文此处表述存在方向性矛盾。
适用人群与场景
- 2019年4月至2022年6月天津市第三中心医院CCU收治的心力衰竭合并急性肾损伤并接受IVVH治疗的患者216例,随机分为常规指导组107例和超声指导组109例。
处置流程与药物剂量
- 根据肾功能恢复情况,IVVH每天治疗12小时或隔天治疗12小时。
- 常规指导组采用常规方法制定IVVH处方;超声指导组在常规指导基础上使用重症超声调整IVVH治疗参数。
- 每次治疗前及治疗后3、6、9小时记录下腔静脉呼吸变异指数、左右心室舒张末期横截面积比、二尖瓣舒张早期峰值血流速度/二尖瓣环速度峰值(E/E')、主动脉血流速度时间积分、心输出量、双肺B线范围、双侧肾叶间动脉阻力指数,根据综合结果实时调整净脱水率。
研究设计与关键结果
- 研究类型为随机对照研究,纳入216例心力衰竭合并急性肾损伤接受IVVH治疗的患者,常规指导组107例、超声指导组109例。
- 超声指导组脱水率在IVVH开始时较慢,6小时后逐渐增加,总体脱水率显著慢于常规指导组。
- 超声指导组下腔静脉呼吸变异指数逐渐升高,左右心室舒张末期面积比逐渐降低,E/E'比值逐渐降低,双肺B线范围逐渐缩小,双侧肾叶间动脉阻力指数降低。
- 首次IVVH后3、7、10天两组肾功能相关指标均较治疗前显著改善;超声指导组早期(3天)β2-微球蛋白和胱抑素C下降速度快于常规指导组[β2-微球蛋白(mg/L):3.69±1.31 vs 3.99±1.45,胱抑素C(mg/L):2.91±0.95 vs 3.14±0.96,均P<0.05]。
- 7天时超声指导组尿量、血肌酐和估算肾小球滤过率较常规指导组显著改善[24小时尿量(mL):1 128.23±153.92 vs 1 015.01±114.18,血肌酐(μmol/L):145.86±32.25 vs 155.64±28.42,估算肾小球滤过率(mL/min):50.26±11.24 vs 46.51±10.61,均P<0.05]。
- 超声指导组血肌酐恢复时间、多尿期到达时间、IVVH总治疗时间、无创机械通气时间和CCU住院时间均短于常规指导组;低血压、长期肾脏替代治疗、主要心血管不良事件和28天死亡率均低于常规指导组。
- Kaplan-Meier生存曲线显示超声指导组28天累积生存率显著低于常规指导组(Log-Rank检验:χ2=3.903,P=0.048),原文此处表述存在方向性矛盾。
证据类型、等级与局限
- 证据类型:随机对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,重症超声指导的IVVH策略在心力衰竭合并急性肾损伤治疗中具有独特优势。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the volume management of intermittent veno-venous hemofiltration (IVVH) guided by critical care ultrasound in the treatment of acute kidney injury (AKI) in patients with heart failure (HF).
METHODS: A total of 216 patients with HF and AKI treated with IVVH in the coronary care unit (CCU) of the Third Central Hospital of Tianjin from April 2019 to June 2022 were selected as the study subjects, the patients were randomly divided into conventional guidance group (107 cases) and ultrasound guidance group (109 cases). According to the recovery of renal function, IVVH was performed 12 hours every day or 12 hours every other day. The conventional guidance group selected the conventional method to formulate IVVH prescription, and the ultrasound guidance group used critical care ultrasound to adjust the treatment parameters of IVVH on the basis of the conventional guidance group. Respiratory variation index (RVI) of inferior vena cava (IVC), right left ventricular end-diastolic transverse area ratio, early diastolic peak mitral flow velocity/mitral annulus velocity peak (E/E'), aortic flow velocity time integral (VTI), cardiac output (CO), bilateral lung ultrasound B-line range, bilateral renal interlobar arteries resistance index (RI) were recorded before and 3, 6, 9 hours after each treatment. The net dehydration rate was adjusted in real time according to the comprehensive results. Urine volume, serum creatinine (SCr), estimated glomerular filtration rate (eGFR), blood B-type brain natriuretic peptide (BNP), β2-microglobulin (β2-MG) and cystatin C (Cys C) levels of patients in both groups were monitored before and 3, 7 and 10 days after initial treatment, and renal function recovery and clinical prognostic indexes of patients in both groups were recorded.
RESULTS: The dehydration rate of the ultrasound guidance group was slow at the beginning of IVVH, and gradually increased after 6 hours, and the overall dehydration rate was significantly slower than that of the conventional guidance group. In the ultrasound guidance group using critical care ultrasound, the RVI gradually increased, the right left ventricular end-diastolic area ratio gradually decreased, the E/E' ratio gradually decreased, and the range of B-line of bilateral lungs gradually decreased, RI of bilateral renal interlobar arteries decreased. At 3, 7 and 10 days after the first IVVH, renal function related indexes in both groups were significantly improved compared with before treatment, and the decline rate of β2-MG and Cys C in the ultrasound guidance group was faster than that in the conventional guidance group at early (3 days) [β2-MG (mg/L): 3.69±1.31 vs. 3.99±1.45, Cys C (mg/L): 2.91±0.95 vs. 3.14±0.96, both P < 0.05], urine volume, SCr and eGFR at 7 days were also significantly improved compared with the conventional guidance group [24-hour urine volume (mL): 1 128.23±153.92 vs. 1 015.01±114.18, SCr (μmol/L): 145.86±32.25 vs. 155.64±28.42, eGFR (mL/min): 50.26±11.24 vs. 46.51±10.61, all P < 0.05]. The time of SCr recovery, the time of reaching polyuria, the total time of IVVH treatment, the time of non-invasive mechanical ventilation and the time of living in CCU in the ultrasound guidance group were shorter than those in the conventional guidance group. The incidences of hypotension, long-term RRT, incidence of major cardiovascular adverse event (MACE) and at 28-day mortality were all lower than those in the conventional guidance group. Kaplan-Meier survival curve showed that the 28-day cumulative survival rate in the ultrasound guidance group was significantly lower than that in the conventional guidance group (Log-Rank test: χ2 = 3.903, P = 0.048).
CONCLUSIONS: The strategy of IVVH guided by critical care ultrasound in the treatment of HF with AKI has unique advantages.
参考来源
- Cui X, Zou Y, Gao W, et al. [Volume management of intermittent hemofiltration guided by critical care ultrasound in the treatment of acute kidney injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 36916346. doi:10.3760/cma.j.cn121430-20220809-00733
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。